Unlock instant, AI-driven research and patent intelligence for your innovation.

Fibrosis causing agent

a fibrosis-causing agent and agent technology, applied in the field of fibrosis-causing agents, can solve the problem that does not necessarily produce the effect of reducing lung capacity as desired, and achieve the effect of reducing lung capacity

Inactive Publication Date: 2015-02-19
TERUMO KK
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a new fibrosis-causing agent that can effectively induce fibrosis in tissues and reduce lung capacity as desired. The new agent contains a fibrosis inducer and a fibrosis promoter. This new approach solves the problem of previous methods not sufficiently inducing fibrosis.

Problems solved by technology

The present inventors found that the composition disclosed in JP-T-2009-514860 does not necessarily achieve fibrosis sufficiently and hence it does not necessarily produce the effect of reducing the lung capacity as desired.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fibrosis causing agent
  • Fibrosis causing agent
  • Fibrosis causing agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0154]Experiments for fibrosis were carried out in which the fibrosis inducer is sodium alginate and the fibrosis promoter is platelet-rich plasma (PRP).

[0155](Preparation of Aqueous Solution of Sodium Alginate)

[0156]An aqueous solution (0.5% w / v) of sodium alginate was prepared by dissolving 0.15 g of sodium alginate (made by Wako Pure Chemical Industries, Ltd.) in 30 mL of reverse osmosis water (RO water), followed by filtration and sterilization through a sterilizing filter (Millipore 0.22 μm). The resulting solution was a viscous fluid.

[0157]Preparation of Platelet-Rich Plasma (PRP)

[0158]In the first step, 10 mL each of blood was collected into two syringes (10 mL) containing 1.0 mL of anticoagulant ACD-A solution (citric acid glucose solution, made by Terumo Corp.) from the auricular artery of unanesthetized Japanese white rabbits (clean, male, 3.0 to 3.49 kg). The collected blood was transferred to a 15-mL centrifuge tube, which was slowly tumbled for mixing.

[0159]The blood wa...

example 2

[0173]Experiments for fibrosis were carried out in which the fibrosis inducer is sodium alginate and the fibrosis promoter is platelet-rich plasma (PRP). These components were used in combination with calcium chloride as the PRP gelling agent.

[0174]Preparation of aqueous solution of sodium alginate and preparation of platelet-rich plasma (PRP)

[0175]The same procedure as in Example 1 was repeated to prepare the aqueous solution of sodium alginate and the platelet-rich plasma (PRP).

[0176]Preparation of Mixed Solution

[0177]A mixed solution was prepared from the aqueous solution of sodium alginate and the platelet-rich plasma (PRP) which were mixed together in a ratio of 1:1 (by volume). The resulting mixed solution was a viscous liquid.

[0178]Preparation of Aqueous Solution of Calcium Chloride

[0179]An aqueous solution (40 mM) of calcium chloride was prepared by dissolving 0.222 g of calcium chloride (made by Wako Pure Chemical Industries, Ltd.) in reverse osmosis water (RO water) such t...

example 3

[0215]Experiments for fibrosis were carried out in which the fibrosis inducer is iron alginate and the fibrosis promoter is platelet-rich plasma (PRP). These components were used in combination with calcium chloride as the PRP gelling agent.

[0216]Preparation of Aqueous Dispersion of Iron Alginate

[0217]An aqueous solution (1% w / v) of iron chloride was prepared by dissolving 5.0 g of iron chloride (made by Wako Pure Chemical Industries, Ltd.) in 500 mL of reverse osmosis water (RO water).

[0218]Also, an aqueous solution (1% w / v) of sodium alginate was prepared by dissolving 1.5 g of sodium alginate (made by Wako Pure Chemical Industries, Ltd.) in 150 mL of reverse osmosis water (RO water).

[0219]The aqueous solution of sodium alginate (in atomized form) was added to the aqueous solution of iron chloride being swirled, so that there was obtained iron alginate in particulate form. The aqueous dispersion of iron alginate was sifted through a sieve with an opening of 100 μm and then thoroug...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application is based on Japanese Application No. 2013-169747, filed on Aug. 19, 2013, the contents of which are incorporated herein by reference.BACKGROUND OF THE DISCLOSURE[0002]The present description relates to a fibrosis-causing agent.[0003]Among a large variety of pulmonary diseases which hamper normal respiration is chronic obstructive pulmonary disease (COPD). It includes at least one of asthma, pulmonary emphysema, and chronic bronchitis, which occludes the lung. These diseases often give rise to their symptoms at one time, thereby making it difficult to determine which one of them causes lung occlusion in each case. COPD remains unchanged for several months and hence chronic bronchitis is clinically identified from the continued reduction of expiration for two or more years. The most serious symptoms relating to COPD are chronic bronchitis and pulmonary emphysema.[0004]The pulmonary emphysema is characterized by an extraordin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/14A61K47/02A61K31/734
CPCA61K35/19A61K47/02A61K31/734A61K9/007A61K35/16A61K38/363A61K38/4833A61K45/06A61P11/00A61P43/00A61K2300/00
Inventor HATA, SUGURUTADA, YUICHIAKUTAGAWA, AYAKA
Owner TERUMO KK